Global Waldenstrom Macroglobulinemia Therapeutics Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 106554
- Pages: 118
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Waldenstrom Macroglobulinemia Therapeutics market in this environment.
In terms of revenue, this research report indicated that the global Waldenstrom Macroglobulinemia Therapeutics market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Waldenstrom Macroglobulinemia Therapeutics industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The BeiGene(Beijing) Co.,Ltd aims at producing XX K Units Waldenstrom Macroglobulinemia Therapeutics in 2020, with XX % production to take place in global market, Calithera Biosciences, Inc. accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Waldenstrom Macroglobulinemia Therapeutics Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Waldenstrom Macroglobulinemia Therapeutics Market
BeiGene(Beijing) Co.,Ltd
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
...
Major Type of Waldenstrom Macroglobulinemia Therapeutics Covered in Prudent Markets report:
CB-839
Copanlisib Hydrochloride
DI-B4
Entospletinib
Everolimus
FV-162
Others
Application Segments Covered in Prudent Markets Market
Clinic
Hospital
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Waldenstrom Macroglobulinemia Therapeutics Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 CB-839 -Product Introduction and Major Manufacturers
1.1.2 Copanlisib Hydrochloride -Product Introduction and Major Manufacturers
1.1.3 DI-B4 -Product Introduction and Major Manufacturers
1.1.4 Entospletinib -Product Introduction and Major Manufacturers
1.1.5 Everolimus -Product Introduction and Major Manufacturers
1.1.6 FV-162 -Product Introduction and Major Manufacturers
1.1.7 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Waldenstrom Macroglobulinemia Therapeutics Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Waldenstrom Macroglobulinemia Therapeutics Market
3.1.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Waldenstrom Macroglobulinemia Therapeutics Market
3.2.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Waldenstrom Macroglobulinemia Therapeutics Market
3.3.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Waldenstrom Macroglobulinemia Therapeutics Market
3.4.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Waldenstrom Macroglobulinemia Therapeutics Market
3.5.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Market
3.6.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Waldenstrom Macroglobulinemia Therapeutics Market
3.7.1 Top Companies leading Waldenstrom Macroglobulinemia Therapeutics Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Waldenstrom Macroglobulinemia Therapeutics Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Waldenstrom Macroglobulinemia Therapeutics Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Waldenstrom Macroglobulinemia Therapeutics Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales and Growth Rate (2021-2027)
5.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value and Growth Rate (2021-2027)
6 Waldenstrom Macroglobulinemia Therapeutics Competitive Analysis
6.1 BeiGene(Beijing) Co.,Ltd
6.1.1 BeiGene(Beijing) Co.,Ltd Company Profiles
6.1.2 BeiGene(Beijing) Co.,Ltd Product Introduction
6.1.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Calithera Biosciences, Inc.
6.2.1 Calithera Biosciences, Inc. Company Profiles
6.2.2 Calithera Biosciences, Inc. Product Introduction
6.2.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Celgene Corporation
6.3.1 Celgene Corporation Company Profiles
6.3.2 Celgene Corporation Product Introduction
6.3.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Genentech, Inc.
6.4.1 Genentech, Inc. Company Profiles
6.4.2 Genentech, Inc. Product Introduction
6.4.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Genmab A/S
6.5.1 Genmab A/S Company Profiles
6.5.2 Genmab A/S Product Introduction
6.5.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Gilead Sciences, Inc.
6.6.1 Gilead Sciences, Inc. Company Profiles
6.6.2 Gilead Sciences, Inc. Product Introduction
6.6.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Hutchison MediPharma Limited
6.7.1 Hutchison MediPharma Limited Company Profiles
6.7.2 Hutchison MediPharma Limited Product Introduction
6.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Idera Pharmaceuticals, Inc.
6.8.1 Idera Pharmaceuticals, Inc. Company Profiles
6.8.2 Idera Pharmaceuticals, Inc. Product Introduction
6.8.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 IGF Oncology, LLC.
6.9.1 IGF Oncology, LLC. Company Profiles
6.9.2 IGF Oncology, LLC. Product Introduction
6.9.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Incyte Corporation
6.10.1 Incyte Corporation Company Profiles
6.10.2 Incyte Corporation Product Introduction
6.10.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Karyopharm Therapeutics, Inc.
6.12 Merck KGaA
6.13 Millennium Pharmaceuticals, Inc.
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
